Published in Chest on October 01, 2005
Rat and human HARE/stabilin-2 are clearance receptors for high- and low-molecular-weight heparins. Am J Physiol Gastrointest Liver Physiol (2009) 0.90
Long-term use of daily subcutaneous low molecular weight heparin in cancer patients with venous thromboembolism: why hesitate any longer? Support Care Cancer (2008) 0.82
Differentiation of parenteral anticoagulants in the prevention and treatment of venous thromboembolism. Thromb J (2011) 0.80
Thromboembolism. BMJ Clin Evid (2011) 0.79
Beyond prejudice: are negative evaluations the problem and is getting us to like one another more the solution? Behav Brain Sci (2012) 18.61
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med (2012) 11.86
Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med (2010) 9.92
Fondaparinux for the treatment of superficial-vein thrombosis in the legs. N Engl J Med (2010) 5.65
Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med (2004) 4.52
Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med (2013) 4.43
Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst (2002) 4.33
Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med (2004) 4.30
Effect of a decision aid on knowledge and treatment decision making for breast cancer surgery: a randomized trial. JAMA (2004) 4.18
Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med (2007) 3.64
Vitamin C as an antioxidant: evaluation of its role in disease prevention. J Am Coll Nutr (2003) 3.34
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med (2011) 3.30
Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci U S A (2005) 3.30
Ascorbic-acid transporter Slc23a1 is essential for vitamin C transport into the brain and for perinatal survival. Nat Med (2002) 2.90
Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci U S A (2007) 2.71
Helping patients make informed choices: a randomized trial of a decision aid for adjuvant chemotherapy in lymph node-negative breast cancer. J Natl Cancer Inst (2003) 2.51
Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci U S A (2008) 2.50
Major contribution of tubular secretion to creatinine clearance in mice. Kidney Int (2009) 2.46
The Kitty Genovese murder and the social psychology of helping: the parable of the 38 witnesses. Am Psychol (2007) 2.23
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J (2013) 2.21
Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery? Anesthesiology (2006) 2.18
Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16. J Clin Oncol (2007) 2.15
A randomised trial comparing preoperative to perioperative chemotherapy in early-stage non-small-cell lung cancer (IFCT 0002 trial). Eur J Cancer (2013) 2.14
Oxalic acid excretion after intravenous ascorbic acid administration. Metabolism (2009) 2.14
Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet (2011) 2.09
Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol (2005) 2.06
Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial. Ann Intern Med (2011) 1.98
Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. PLoS One (2010) 1.92
High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med (2014) 1.91
Clinical practice guidelines for the care and treatment of breast cancer: follow-up after treatment for breast cancer (summary of the 2005 update). CMAJ (2005) 1.89
Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med (2007) 1.84
Human adrenal glands secrete vitamin C in response to adrenocorticotrophic hormone. Am J Clin Nutr (2007) 1.60
Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer. Clin Cancer Res (2010) 1.57
Prevalence of poor biological response to clopidogrel: a systematic review. Thromb Haemost (2012) 1.57
ACCF/AHA clinical competence statement on cardiac imaging with computed tomography and magnetic resonance: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training. J Am Coll Cardiol (2005) 1.56
Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol (2005) 1.54
Coverage with evidence development: the Ontario experience. Int J Technol Assess Health Care (2011) 1.53
Inhibition of the intestinal glucose transporter GLUT2 by flavonoids. FASEB J (2006) 1.53
Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer. CMAJ (2004) 1.51
Using administrative databases to measure waiting times for patients undergoing major cancer surgery in Ontario, 1993-2000. Can J Surg (2005) 1.49
Clinical practice guidelines for the care and treatment of breast cancer: 16. Locoregional post-mastectomy radiotherapy. CMAJ (2004) 1.46
Central venous catheter care for the patient with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol (2013) 1.46
Intravenously administered vitamin C as cancer therapy: three cases. CMAJ (2006) 1.43
Hypoxia-inducible factor-1alpha stabilization in nonhypoxic conditions: role of oxidation and intracellular ascorbate depletion. Mol Biol Cell (2007) 1.41
Feasibility of an easy-to-use risk score in the prevention of venous thromboembolism and placental vascular complications in pregnant women: a prospective cohort of 2736 women. Thromb Res (2008) 1.41
Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study--NCIC CTG MA.5. J Clin Oncol (2005) 1.40
A randomized double-blind trial of upward progressive versus degressive compressive stockings in patients with moderate to severe chronic venous insufficiency. J Vasc Surg (2012) 1.40
ACCF/AHA clinical competence statement on cardiac imaging with computed tomography and magnetic resonance. Circulation (2005) 1.40
Clinical relevance of symptomatic superficial-vein thrombosis extension: lessons from the CALISTO study. Blood (2013) 1.39
Functional hypoparathyroidism in postmenopausal women with fragility fracture. Joint Bone Spine (2011) 1.39
Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One (2012) 1.35
Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost (2006) 1.35
Vitamin C transporter Slc23a1 links renal reabsorption, vitamin C tissue accumulation, and perinatal survival in mice. J Clin Invest (2010) 1.33
Compliance and stability of INR of two oral anticoagulants with different half-lives: a randomised trial. Thromb Haemost (2003) 1.29
Comparison of the genomic structure and variation in the two human sodium-dependent vitamin C transporters, SLC23A1 and SLC23A2. Hum Genet (2004) 1.27
Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer. Free Radic Biol Med (2011) 1.27
Lessons learned from the Decision Board: a unique and evolving decision aid. Health Expect (2000) 1.25
Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study. Thromb Haemost (2013) 1.21
6-Bromo-6-deoxy-L-ascorbic acid: an ascorbate analog specific for Na+-dependent vitamin C transporter but not glucose transporter pathways. J Biol Chem (2004) 1.16
Genomic and functional analysis of the sodium-dependent vitamin C transporter SLC23A1-SVCT1. Genes Nutr (2007) 1.16
Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials. J Thorac Oncol (2007) 1.15
Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncologist (2003) 1.13
Flavonoid inhibition of sodium-dependent vitamin C transporter 1 (SVCT1) and glucose transporter isoform 2 (GLUT2), intestinal transporters for vitamin C and Glucose. J Biol Chem (2002) 1.13
Influence of hospital characteristics on operative death and survival of patients after major cancer surgery in Ontario. Can J Surg (2006) 1.12
High-dose oral vitamin C partially replenishes vitamin C levels in patients with Type 2 diabetes and low vitamin C levels but does not improve endothelial dysfunction or insulin resistance. Am J Physiol Heart Circ Physiol (2005) 1.11
Standard-dose vs high-dose multivitamin supplements for HIV. JAMA (2013) 1.08
Genetic variation in the sodium-dependent vitamin C transporters, SLC23A1, and SLC23A2 and risk for preterm delivery. Am J Epidemiol (2005) 1.08
Superficial vein thrombosis: risk factors, diagnosis, and treatment. Curr Opin Pulm Med (2003) 1.08
Cystatin C-based equations in renal transplantation: moving toward a better glomerular filtration rate prediction? Transplantation (2008) 1.06
Radiation therapy and tamoxifen: concurrent or sequential? That is the question. J Clin Oncol (2004) 1.06
Cloning and functional characterization of the mouse fructose transporter, GLUT5. Biochim Biophys Acta (2002) 1.05
Hemoglobin and plasma vitamin C levels in patients on peritoneal dialysis. Perit Dial Int (2010) 0.99
The role of mannosylated enzyme and the mannose receptor in enzyme replacement therapy. Am J Hum Genet (2005) 0.98
Parenteral ascorbate as a cancer therapeutic: a reassessment based on pharmacokinetics. Antioxid Redox Signal (2013) 0.97
Thromboprophylaxis in acute medical patients: need for an implementation strategy. Haematologica (2002) 0.97
Genetic variation in sodium-dependent vitamin C transporters SLC23A1 and SLC23A2 and risk of advanced colorectal adenoma. Nutr Cancer (2008) 0.96
Vitamins C and E and the prevention of preeclampsia. N Engl J Med (2006) 0.96
Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thromb Haemost (2009) 0.94
Docetaxel-containing adjuvant chemotherapy in patients with early stage breast cancer. Consistency of effect independent of nodal and biomarker status: a meta-analysis of 14 randomized clinical trials. Breast Cancer Res Treat (2012) 0.93
The experience of conducting Mortality and Morbidity reviews in a pediatric interventional radiology service: a retrospective study. J Vasc Interv Radiol (2008) 0.93
A prospective long-term study of 220 patients with a retrievable vena cava filter for secondary prevention of venous thromboembolism. Chest (2007) 0.93
Impaired adrenal catecholamine system function in mice with deficiency of the ascorbic acid transporter (SVCT2). FASEB J (2003) 0.92
Optimal low-molecular-weight heparin regimen in major orthopaedic surgery. A meta-analysis of randomised trials. Thromb Haemost (2003) 0.92
UPLC MS/MS assay for routine quantification of dabigatran - a direct thrombin inhibitor - in human plasma. J Pharm Biomed Anal (2011) 0.91
Bystander responses to a violent incident in an immersive virtual environment. PLoS One (2013) 0.90
Intravenous thrombolytic therapy in patients with phlegmasia caerulea dolens. Haematologica (2006) 0.89